---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References"
description: "Reference list for the formulary evidence report on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer. 256 cited documents."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References

<a id="references"></a>

## 5 References

1. [Abraxane prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf)
2. [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)
3. [Allen (2010)](https://pubmed.ncbi.nlm.nih.gov/20873957/)
4. [Allison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928404/)
5. [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)
6. [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)
7. [American Cancer Society Key Statistics for Breast Cancer (2026)](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html)
8. [Andrade et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112279/)
9. [André et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31091374/)
10. [André et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33246021/)
11. [Aromasin prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020753s025lbl.pdf)
12. [AstraZeneca SERENA-4 update announcement (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html)
13. [AstraZeneca Truqap blister pack availability notice (2024)](https://associationdatabase.com/aws/MSHO/asset_manager/get_file/909026)
14. [Atre et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38816556/)
15. [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)
16. [Bardia et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39282896/)
17. [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/)
18. [Barratt et al. (2026)](https://olema.com/wp-content/uploads/2026/04/Olema_AACR_2026_Poster-2950_Final-Digital-Poster.pdf)
19. [Baselga et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5705195/)
20. [Behan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695835/)
21. [Bello et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42002527/)
22. [Benvenuti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10136132/)
23. [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)
24. [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)
25. [Bidard et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454637/)
26. [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)
27. [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)
28. [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)
29. [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)
30. [Bramley et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27248201/)
31. [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)
32. [Brufsky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11455714/)
33. [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)
34. [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)
35. [Burstein et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38478799/)
36. [Cabel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41260263/)
37. [Cadirov et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12564138/)
38. [CADTH capivasertib reimbursement recommendation (2024)](https://canjhealthtechnol.ca/index.php/cjht/article/download/PC0341/2134?inline=1)
39. [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)
40. [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)
41. [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)
42. [Celcuity Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1603454/000119312526450161/celc-20260930.htm)
43. [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)
44. [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)
45. [Chan et al. (2023c)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OPERA-01-TiP_12-5-23.pdf)
46. [Chan et al. (2024)](https://aacrjournals.org/cancerres/article/84/9_Supplement/PS15-04/744001/Abstract-PS15-04-A-Phase-1b-2-study-of)
47. [Chandarlapaty et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5063698/)
48. [Ciruelos et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8210974/)
49. [Cleeland et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25193423/)
50. [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)
51. [ClinicalTrials.gov NCT04505826 results](https://clinicaltrials.gov/study/NCT04505826?tab=results)
52. [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)
53. [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)
54. [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)
55. [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)
56. [CMS ADLT list (2026)](https://cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)
57. [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files)
58. [CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026)](https://www.cms.gov/files/zip/26clabq4.zip)
59. [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)
60. [CMS National Coverage Determination 90.2 (2020)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372)
61. [CMS Quality ID 047 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_047_MIPSCQM.pdf)
62. [CMS Quality ID 143 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_143_MIPSCQM.pdf)
63. [CMS Quality ID 144 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_144_MIPSCQM.pdf)
64. [CMS Quality ID 453 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_453_MIPSCQM.pdf)
65. [CMS Quality ID 457 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_457_MIPSCQM.pdf)
66. [Comerford et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39631724/)
67. [Cong et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9596506/)
68. [Cortes et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21376385/)
69. [Curigliano et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41780642/)
70. [Curigliano et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13091516/)
71. [Daily et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33750642/)
72. [Datroway prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761394s003lbl.pdf)
73. [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)
74. [Dilawari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11588547/)
75. [Dilawari et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40763319/)
76. [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)
77. [Enhertu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761139s041s043lbl.pdf)
78. [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)
79. [EU CTIS 2023-505871-63-00](https://euclinicaltrials.eu/ctis-public/view/2023-505871-63-00)
80. [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)
81. [FDA (2018)](https://www.fda.gov/media/71195/download)
82. [FDA camizestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative)
83. [FDA gedatolisib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally)
84. [FDA Guardant360 CDx SSED S021 (2025)](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S021B.pdf)
85. [FDA imlunestrant and abemaciclib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or)
86. [FDA imlunestrant approval notice (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)
87. [FDA vepdegestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)
88. [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)
89. [Franklin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11213812/)
90. [Fribbens et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27269946/)
91. [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)
92. [Gauthier et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29556908/)
93. [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)
94. [Giuliano et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31494037/)
95. [Gogate et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8364673/)
96. [Goyal et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31060392/)
97. [Goyal et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32755262/)
98. [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)
99. [Greer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32023526/)
100. [Gupta et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690425/)
101. [Halaven prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201532s023lbl.pdf)
102. [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)
103. [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)
104. [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)
105. [Hao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4922814/)
106. [Henry et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35759724/)
107. [Howlader et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29593010/)
108. [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)
109. [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)
110. [International Agency for Research on Cancer GLOBOCAN breast fact sheet (2026)](https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf)
111. [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)
112. [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf)
113. [Jaber Chehayeb et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9709649/)
114. [Jeselsohn et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911210/)
115. [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)
116. [Jhaveri et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13496148/)
117. [Jhaveri et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12972957/)
118. [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)
119. [Kalinsky et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37207300/)
120. [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)
121. [Kalinsky et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42926108/)
122. [Kamal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397748/)
123. [Kashiwa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13723614/)
124. [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)
125. [Kuksis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8168821/)
126. [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)
127. [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11774713/)
128. [Liang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42009253/)
129. [Liao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13710441/)
130. [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)
131. [Lin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11590753/)
132. [Lin et al. (2025a)](https://www.annalsofoncology.org/article/S0923-7534(25)01845-9/fulltext)
133. [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)
134. [Litton et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30110579/)
135. [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/)
136. [Lloyd et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360509/)
137. [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340905/)
138. [Lloyd et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39179659/)
139. [Lloyd et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770935/)
140. [Lloyd et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42413061/)
141. [Lord et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8804182/)
142. [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)
143. [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)
144. [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)
145. [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)
146. [Mayer et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38513188/)
147. [Mayer et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41125211/)
148. [Mayer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674676/)
149. [Meisel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13558280/)
150. [Mertz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9307669/)
151. [Modi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/)
152. [Modi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705423/)
153. [Moy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34324366/)
154. [Moy et al. (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01533)
155. [Moy et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02807)
156. [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)
157. [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)
158. [NCI Thesaurus (2026)](https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C176877)
159. [Neuss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27868581/)
160. [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)
161. [Nguyen and Mital (2025)](https://pubmed.ncbi.nlm.nih.gov/39630382/)
162. [Nguyen and Mital (2026)](https://pubmed.ncbi.nlm.nih.gov/42305034/)
163. [NICE TA1036 committee discussion (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/3-Committee-discussion)
164. [NICE TA1036 recommendation (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/1-Recommendations)
165. [NICE TA1168 terminated appraisal (2026)](https://www.nice.org.uk/guidance/ta1168/chapter/advice)
166. [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)
167. [Okeke et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397977/)
168. [Olema Oncology AACR 2026 preclinical data announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-preclinical-data-palazestrant-and-op)
169. [Olema Oncology corporate name change announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-corporate-name-change)
170. [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)
171. [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)
172. [Olema Oncology ESMO 2025 ribociclib results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-data-phase-1b2-trial-palazestrant)
173. [Olema Oncology Fast Track designation announcement (2022)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-receives-fda-fast-track-designation-op-1250)
174. [Olema Oncology first quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-first-quarter-2026-financial-and)
175. [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)
176. [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)
177. [Olema Oncology fourth quarter and full year 2025 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-fourth-quarter-and-full-year-2025)
178. [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)
179. [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)
180. [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)
181. [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)
182. [Olema Oncology SABCS 2023 combination results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-demonstrates-attractive)
183. [Olema Oncology SABCS 2024 announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-presents-updated-clinical-results-palazestrant)
184. [Olema Oncology SABCS 2026 presentations announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-present-combination-data-palazestrant-and-op-3136)
185. [Olema Oncology second quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2025-financial-and)
186. [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)
187. [Olema Oncology third quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2025-financial-and)
188. [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)
189. [Oliveira et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/39214106/)
190. [Oliveira et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39481395/)
191. [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)
192. [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)
193. [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)
194. [Pan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5734609/)
195. [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)
196. [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)
197. [Pezzolato et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37571974/)
198. [Piccart et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/)
199. [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf)
200. [Pistilli et al. (2024)](https://olema.com/wp-content/uploads/2024/06/Olema_Final-ASCO2024_OPERA-01-TiP-Poster_6-2-24.pdf)
201. [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)
202. [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)
203. [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/)
204. [Revtorpyk prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219908Orig1s000lbl.pdf)
205. [Reyes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6738320/)
206. [Robson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28578601/)
207. [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/)
208. [Roche giredestrant New Drug Application acceptance announcement (2026)](https://www.roche.com/media/releases/med-cor-2026-02-20)
209. [Rocque et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7666754/)
210. [Rocque et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12596709/)
211. [Rosenzweig et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30547962/)
212. [Royce et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12393668/)
213. [Rugo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36027558/)
214. [Rugo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37633306/)
215. [Rugo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39637900/)
216. [Rugo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11758200/)
217. [Rugo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770937/)
218. [Sammons et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40163696/)
219. [Schiavon et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4998737/)
220. [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)
221. [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)
222. [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)
223. [Siegel et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38776491/)
224. [Sorensen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22617734/)
225. [Sun et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467758/)
226. [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)
227. [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)
228. [Tolaney et al. (2025)](https://ir.olema.com/static-files/e5b62d98-7b5b-46fa-9d9a-bbc378f6749b)
229. [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)
230. [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)
231. [Toy et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3903423/)
232. [Trodelvy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761115s064lbl.pdf)
233. [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)
234. [Tung et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32243226/)
235. [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)
236. [Turner et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39476340/)
237. [Twelves et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4243003/)
238. [Van Poznak et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29035643/)
239. [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)
240. [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf)
241. [Verzenio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208716s022lbl.pdf)
242. [Wan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23866016/)
243. [Waters et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129926/)
244. [Wheeler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10242847/)
245. [WHO Proposed INN List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)
246. [WHO Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)
247. [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)
248. [Wolff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37284804/)
249. [Wood et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5703387/)
250. [Wortelboer et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41207182/)
251. [Wortelboer et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41270788/)
252. [Wu et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37975961/)
253. [Xeloda prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020896s052lbl.pdf)
254. [Yin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12831935/)
255. [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/)
256. [Zhang et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832676/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
